Breaking a Vicious Cycle
Daniel F. Hayes, Jeff D. Allen, Carolyn C. Compton et al. · Science Translational Medicine · 2013
Despite prodigious advances in tumor biology research, few tumor-biomarker tests have been adopted as standard clinical practice. This lack of reliable tests stems from a vicious cycle of undervaluation, resulting from inconsistent regulatory standards and reimbursement, as well as insufficient investment in research and development, scrutiny of biomarker publications by journals, and evidence of analytical validity and clinical utility. We offer recommendations designed to serve as a roadmap to break this vicious cycle and call for a national dialogue, as changes in regulation, reimbursement, investment, peer review, and guidelines development require the participation of all stakeholders.
Cited by 122 works. doi:10.1126/scitranslmed.3005950
Authors
- Daniel F. Hayes
- Jeff D. Allen
- Carolyn C. Compton
- Gary George Gustavsen
- Debra G. B. Leonard
- Robert Thomas Mccormack
- Lee N. Newcomer
- Kristin Ciriello Pothier
- David F. Ransohoff
- Richard L. Schilsky
- Ellen V. Sigal
- Sheila E. Taube
- Sean Tunis
References
- CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
- CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials
- American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
- Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers
- Tumor Marker Utility Grading System: a Framework to Evaluate Clinical Utility of Tumor Markers
- American Society of Clinical Oncology Provisional Clinical Opinion: Testing for KRAS Gene Mutations in Patients With Metastatic Colorectal Carcinoma to Predict Response to Anti–Epidermal Growth Factor Receptor Monoclonal Antibody Therapy
- The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group
- Clinical Trial Designs for Predictive Marker Validation in Cancer Treatment Trials
- Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials
- Genomics and Drug Response